These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12396745)

  • 21. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.
    Cheng-Lai A; Levine A
    Heart Dis; 2000; 2(4):326-33. PubMed ID: 11728276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors.
    Bando Y; Ushiogi Y; Okafuji K; Toya D; Tanaka N; Fujisawa M
    J Int Med Res; 1999; 27(2):53-64. PubMed ID: 10446691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Severe electrolyte imbalance and edema in therapy with rosiglitazone].
    Kuschel U; Hesselbarth N; Herrmann A; Hippius M; Hoffmann A
    Med Klin (Munich); 2002 Sep; 97(9):553-5. PubMed ID: 12371084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
    Diamant M; Heine RJ
    Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    Jones TA; Sautter M; Van Gaal LF; Jones NP
    Diabetes Obes Metab; 2003 May; 5(3):163-70. PubMed ID: 12681023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone-induced granulomatous hepatitis.
    Dhawan M; Agrawal R; Ravi J; Gulati S; Silverman J; Nathan G; Raab S; Brodmerkel G
    J Clin Gastroenterol; 2002; 34(5):582-4. PubMed ID: 11960075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. After avandia: the use of antidiabetic drugs in patients with heart failure.
    Khalaf KI; Taegtmeyer H
    Tex Heart Inst J; 2012; 39(2):174-8. PubMed ID: 22740727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
    Füchtenbusch M; Standl E; Schatz H
    Exp Clin Endocrinol Diabetes; 2000; 108(3):151-63. PubMed ID: 10926309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.
    Hussein Z; Wentworth JM; Nankervis AJ; Proietto J; Colman PG
    Med J Aust; 2004 Nov; 181(10):536-9. PubMed ID: 15540964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Medication of the month. Rosiglitazone (Avandia)].
    Scheen AJ
    Rev Med Liege; 2002 Apr; 57(4):236-9. PubMed ID: 12073798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy with glitazones--a risk for cardiovascular disease?].
    Rottlaender D; Michels G; Erdmann E; Hoppe UC
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2629-32. PubMed ID: 18050028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pioglitazone and rosiglitazone for diabetes.
    Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.
    Reynolds LR; Konz EC; Frederich RC; Anderson JW
    Diabetes Obes Metab; 2002 Jul; 4(4):270-5. PubMed ID: 12099976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular injury in a patient receiving rosiglitazone. A case report.
    Al-Salman J; Arjomand H; Kemp DG; Mittal M
    Ann Intern Med; 2000 Jan; 132(2):121-4. PubMed ID: 10644273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thiazolidinediones in diabetes: current status and future outlook.
    Camp HS
    Curr Opin Investig Drugs; 2003 Apr; 4(4):406-11. PubMed ID: 12808879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.